This document is a published patent application from the USPTO concerning "Heterodimeric Human IgG1 Polypeptides with Isoelectric Point Modifications." The application, identified as US20260085132A1, was filed on November 13, 2025, and published on March 26, 2026. It describes novel compositions and methods for purifying specific heterodimer immunoglobulin variants from mixtures containing homodimer variants by altering the isoelectric points of the individual polypeptide chains.

This patent application provides technical information related to the development and purification of therapeutic proteins, specifically antibodies. While it does not impose direct compliance obligations on regulated entities, it is relevant for companies involved in biopharmaceutical research and development, particularly those working with antibody-based therapeutics. Compliance officers in the pharmaceutical and biotechnology sectors should be aware of this publication as it may influence future product development and intellectual property strategies.